ライフサイエンスコーパス: haemophilia

1 s are vital for people with diseases such as haemophilia.

2 the risk of HHV-8 infection in patients with haemophilia.

3 Only three sera from patients with haemophilia (1/84) or from intravenous drug users (2/63)

4 Haemophilia A and B are hereditary haemorrhagic disorder

5 ss to and aid understanding of the causes of haemophilia A at the molecular level we have constructed

6 to, and aid understanding of, the causes of haemophilia A at the molecular level; previously, the fi

7 a A, replacing previous text editions of the Haemophilia A Database published in Nucleic Acids Resear

8 nce of severe bleeding episodes in dogs with haemophilia A for at least 2.5 years after transplantati

9 Since 1996 the HAMSTeRS (Haemophilia A Mutation, Search, Test and Resource Site)

10 Although deficiencies of factor VIII (haemophilia A) and factor IX (haemophilia B) are well re

11 of factor VIII and the molecular genetics of haemophilia A, a real time update of the biostatistics o

12 common inversions responsible for 1/5 of all haemophilia A, affects the first rather than intron 22 o

13 access to data on the molecular pathology of haemophilia A, replacing previous text editions of the H

14 ng-term control of bleeding in patients with haemophilia A.

15 ucible treatment to maintain haemostasis for haemophilia A.

16 ctor VIII that lead to bleeding disorders in haemophilia A.

17 (ie, inhibitors), which is most frequent in haemophilia A.

18 , and factor X deficiency (one), carriage of haemophilia-A gene (one), and platelet dysfunction (one)

19 In those with severe haemophilia, age-standardised all-cause mortality was st

20 tracted from the plasma of 112 patients with haemophilia and 57 with hypogammaglobulinaemia, as well

21 For those with haemophilia and HIV-1 infection, the corresponding risks

22 y, spinal muscular atrophy, cystic fibrosis, haemophilia and sickle cell disease.

23 The haemophilias are inherited disorders in which one of the

24 usly treated boys younger than 12 years with haemophilia B (</=2 IU/dL [</=2%] endogenous coagulation

25 mutations in these domains in patients with haemophilia B (defective in coagulation factor IX) and t

26 ndrome (MFS), CADASIL, protein S deficiency, haemophilia B and familial hypercholesterolaemia, respec

27 This demonstrates the potential of treating haemophilia B by gene therapy at the natural site of fac

28 The eighth edition of the haemophilia B database lists in an easily accessible for

29 The seventh edition of the haemophilia B database lists in easily accessible form a

30 The sixth edition of the haemophilia B database lists in easily accessible form a

31 te amelioration of the bleeding diathesis in haemophilia B mice.

32 ly cure the coagulation defect in the canine haemophilia B model; however, an immune response directe

33 ns and/or deletions of <30 bp) identified in haemophilia B patients.

34 ns and/or deletions of <30 bp) identified in haemophilia B patients.

35 ns and/or deletions of <30 bp) identified in haemophilia B patients.

36 offers the possibility of converting severe haemophilia B to a milder form of the disease.

37 f factor VIII (haemophilia A) and factor IX (haemophilia B) are well recognised, von Willebrand's dis

38 trials to treat hereditary diseases such as haemophilia B, and have been approved for treatment of l

39 prolonged clotting times in a mouse model of haemophilia B, and remained persistent after induced liv

40 Haemophilia B, or factor IX deficiency, is a X-linked re

41 c patients younger than 12 years with severe haemophilia B.

42 n low bleeding rates in children with severe haemophilia B.

43 expressing human F.IX in adults with severe haemophilia B.

44 ls that were therapeutic in a mouse model of haemophilia B.

45 factor IX cDNA into the livers of dogs with haemophilia B.

46 and important results have been obtained in haemophilia B.

47 Despite improvements in haemophilia care, the availability of clotting factor co

48 tients registered at the Royal Free Hospital Haemophilia Centre, London, UK.

49 Information was extracted from the National Haemophilia Database.

50 ession to AIDS and death in individuals with haemophilia infected with HIV-1 and hepatitis C virus.

51 However, we must not forget that haemophilia is a worldwide disorder that requires signif

52 , 0.0-2.0] joint bleeds/y) and joint health (Haemophilia Joint Health Score >10 of 144 points in 46%

53 We studied 1216 HIV-1-infected haemophilia patients in the UK who were registered with

54 rom liver disease and liver cancer in the UK haemophilia population in individuals both infected and

55 the UK who were registered with the National Haemophilia Register and were alive on Jan 1, 1985.

56 with 5-30% of the normal factor IX have mild haemophilia that may not be recognized until adulthood o

57 or by confounding with other factors such as haemophilia type or severity.

58 In the past, men with haemophilia were likely to die in their youth.

59 For men and boys with severe haemophilia who were not infected with HIV-1, the cumula

60 Most people with haemophilia who were treated with blood products before